Afrodite Lourbakos

Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study

Thomas Voit, Haluk Topaloğlu, Volker Straub et al. · The Lancet Neurology · 2014 · 293 citations

Placebo-controlled Phase 2, Medicine, Duchenne Muscular Dystrophy +5

Arginine-Specific Protease from<i>Porphyromonas gingivalis</i>Activates Protease-Activated Receptors on Human Oral Epithelial Cells and Induces Interleukin-6 Secretion

Afrodite Lourbakos, Jan Potempa, James Travis et al. · Infection and Immunity · 2001 · 235 citations · Full text

Activation of protease-activated receptors by gingipains fromPorphyromonas gingivalis leads to platelet aggregation: a new trait in microbial pathogenicity

Afrodite Lourbakos, YuPing Yuan, Alison L. Jenkins et al. · Blood · 2001 · 231 citations

Cleavage and activation of proteinase‐activated receptor‐2 on human neutrophils by gingipain‐R from <i>Porphyromonas gingivalis</i>

Afrodite Lourbakos, Carla Chinni, Philip E. Thompson et al. · FEBS Letters · 1998 · 169 citations · Full text

A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy

Nathalie Goemans, Eugenio Mercuri, Hirofumi Komaki et al. · Neuromuscular Disorders · 2017 · 119 citations · Full text

Duchenne Muscular Dystrophy, Medicine, Clinical Trials +5